Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria

Reuters12-05

Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria

Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT®-Flex powered by the SOPHiA DDM™ Platform. This integration leverages the proven MSK-IMPACT® assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling (CGP) of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589859798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589859798","market":"fut","top_or_hot":-1,"title":"Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT®-Flex powered by the SOPHiA DDM™ Platform. This integration leverages the proven MSK-IMPACT® assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling (CGP) of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT®-Flex powered by the SOPHiA DDM™ Platform. This integration leverages the proven MSK-IMPACT® assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling (CGP) of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL91Jgd2:1","article_id":"2589859798","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589859798","pubTimestamp":1764897391,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT-Flex powered by the SOPHiA DDM Platform. This integration leverages the proven MSK-IMPACT assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling  of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","BK4539":"次新股","SOPH":"SOPHiA GENETICS SA"},"translate_title":"Sophia Genetics SA与Tyrolpath合作在奥地利推出MSK-IMPACT Flex","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOPH":0.9},"content_text":"Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria\n    \n\n        Sophia Genetics SA has partnered with Tyrolpath, the largest private pathology lab in western Austria, to bring advanced precision oncology solutions to the country. Through this collaboration, Tyrolpath will be the first lab in Austria to adopt MSK-IMPACT®-Flex powered by the SOPHiA DDM™ Platform. This integration leverages the proven MSK-IMPACT® assay from Memorial Sloan Kettering Cancer Center and SOPHiA GENETICS' cloud-based data analysis platform, enabling cost-efficient, flexible, and comprehensive genomic profiling (CGP) of solid tumors. The partnership aims to enhance cancer testing and advance precision oncology for Austrian patients, addressing the growing need for actionable genomic insights in cancer care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589859798","isCrawlerRequest":true}